Abstract
As pregnancy is a hypercoaguable state, the risk for thromboembolic event rises. With thromboembolism being the leading cause of death among pregnant women in developed countries, anticoagulation therapy is needed more commonly. Warfarin teratogenicity and heparin's safety profile have placed enoxaparin as the drug of choice for anticoagulation therapy during pregnancy. While several studies investigated enoxaparin effectiveness during gestation, its fetal safety has been only sparsely studied. The aim of this study was to evaluate fetal safety after enoxaparin exposure during pregnancy.
Original language | English |
---|---|
Pages (from-to) | 526-527 |
Number of pages | 2 |
Journal | Birth Defects Research Part A Clinical and Molecular Teratology |
Volume | 100 |
DOIs | |
State | Published - 1 Jul 2014 |